Drugs / Analatro
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00247078 | Oct 2005 → Oct 2006 | black widow spider envenomation | Instituto Bioclon S.A. de C.V. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00657540 | Oct 2009 → Oct 2014 | black widow spider envenomation | Instituto Bioclon S.A. de C.V. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Analatro | “Instituto Bioclon S.A. de C.V. has developed Analatro®, an antibody fragment (Fab2) containing widow spider (Latrodectus) antivenom” NCT00657540 ↗ |
| Known as | Aracmyn | “The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism” NCT00247078 ↗ |
| Modality | Protein / enzyme biologic | “an antibody fragment (Fab2) containing widow spider (Latrodectus) antivenom” NCT00657540 ↗ |
| Route | Intravenous | “Dose 1 of study medication (50 mL) will be infused intravenously over 10 minutes” NCT00657540 ↗ |